SCHOLAR ROCK HOLDING CORPORATION Increase (Decrease) in Prepaid Expense and Other Assets
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$2.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$4.52M, a 246.69% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $2.04M, a 70.80% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$2.27M, a 6400.00% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$4.09M, a 178.49% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in prepaid expense and other assets for fiscal 2025 was $3.70M, a 35.93% decline from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in prepaid expense and other assets for fiscal 2024 was $5.77M.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$4.53M, a 1506.83% decline from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in prepaid expense and other assets for fiscal 2022 was $322.00K, a 96.23% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.49M 10-Q · filed 2026-08-06 | -$4.76M derived: sum of 3 quarters · filed 2026-08-06 | -$8.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.04M 10-Q · filed 2026-05-07 | -$233.00K derived: sum of 2 quarters · filed 2026-05-07 | -$4.32M derived: sum of 3 quarters · filed 2026-05-07 | -$1.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$6.36M derived: sum of 2 quarters · filed 2026-03-03 | -$3.27M derived: sum of 3 quarters · filed 2026-08-06 | $3.70M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$4.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$1.00M derived: sum of 2 quarters · filed 2026-08-06 | $5.96M 10-Q · filed 2025-11-14 | $6.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $10.05M 10-Q · filed 2026-08-06 | $10.09M derived: sum of 3 quarters · filed 2026-08-06 | $15.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.97M 10-Q · filed 2026-05-07 | $7.00M derived: sum of 2 quarters · filed 2026-05-07 | $12.21M derived: sum of 3 quarters · filed 2026-05-07 | $12.36M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $5.24M derived: sum of 2 quarters · filed 2026-03-03 | $5.39M derived: sum of 3 quarters · filed 2026-03-03 | $5.77M 10-K · filed 2026-03-03 |
| 2024-09-30 | $5.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $5.35M derived: sum of 2 quarters · filed 2025-11-14 | $5.73M 10-Q · filed 2025-11-14 | $4.02M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $142.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $526.00K 10-Q · filed 2025-08-06 | -$1.19M derived: sum of 3 quarters · filed 2025-08-06 | -$2.43M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $384.00K 10-Q · filed 2025-05-14 | -$1.33M derived: sum of 2 quarters · filed 2025-05-14 | -$2.58M derived: sum of 3 quarters · filed 2025-05-14 | -$3.37M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$2.96M derived: sum of 2 quarters · filed 2025-02-27 | -$3.76M derived: sum of 3 quarters · filed 2025-02-27 | -$4.53M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.04M derived: sum of 2 quarters · filed 2024-11-12 | -$2.82M 10-Q · filed 2024-11-12 | -$4.13M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$798.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.57M 10-Q · filed 2024-08-08 | -$2.88M derived: sum of 3 quarters · filed 2024-08-08 | -$7.38M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$773.00K 10-Q · filed 2024-05-07 | -$2.08M derived: sum of 2 quarters · filed 2024-05-07 | -$6.58M derived: sum of 3 quarters · filed 2024-05-07 | -$6.50M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$5.80M derived: sum of 2 quarters · filed 2024-03-19 | -$5.73M derived: sum of 3 quarters · filed 2024-03-19 | $322.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | -$4.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$4.42M derived: sum of 2 quarters · filed 2023-11-07 | $1.63M 10-Q · filed 2023-11-07 | $2.29M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $76.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $6.13M 10-Q · filed 2023-08-09 | $6.78M derived: sum of 3 quarters · filed 2023-08-09 | $10.30M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $6.05M 10-Q · filed 2023-05-09 | $6.70M derived: sum of 2 quarters · filed 2023-05-09 | $10.22M derived: sum of 3 quarters · filed 2023-05-09 | $15.20M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $654.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $4.17M derived: sum of 2 quarters · filed 2023-03-07 | $9.15M derived: sum of 3 quarters · filed 2023-03-07 | $8.53M 10-K · filed 2023-03-07 |
| 2021-09-30 | $3.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $8.49M derived: sum of 2 quarters · filed 2022-11-14 | $7.88M 10-Q · filed 2022-11-14 | $7.04M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $4.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $4.36M 10-Q · filed 2022-08-08 | $3.52M derived: sum of 3 quarters · filed 2022-08-08 | $6.42M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$619.00K 10-Q · filed 2022-05-16 | -$1.46M derived: sum of 2 quarters · filed 2022-05-16 | $1.45M derived: sum of 3 quarters · filed 2022-05-16 | $1.94M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$836.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $2.07M derived: sum of 2 quarters · filed 2022-03-07 | $2.56M derived: sum of 3 quarters · filed 2022-03-07 | $3.36M 10-K · filed 2022-03-07 |
| 2020-09-30 | $2.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $3.39M derived: sum of 2 quarters · filed 2021-11-09 | $4.20M 10-Q · filed 2021-11-09 | $3.94M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $486.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $1.29M 10-Q · filed 2021-08-10 | $1.03M derived: sum of 3 quarters · filed 2021-08-10 | $940.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $806.00K 10-Q · filed 2021-05-13 | $544.00K derived: sum of 2 quarters · filed 2021-05-13 | $454.00K derived: sum of 3 quarters · filed 2021-05-13 | $1.34M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$262.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$352.00K derived: sum of 2 quarters · filed 2021-03-09 | $533.00K derived: sum of 3 quarters · filed 2021-03-09 | $739.00K 10-K · filed 2021-03-09 |
| 2019-09-30 | -$90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $795.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.00M 10-Q · filed 2020-11-09 | $1.17M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $885.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $1.09M 10-Q · filed 2020-08-07 | $1.26M derived: sum of 3 quarters · filed 2020-08-07 | $1.61M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $206.00K 10-Q · filed 2020-05-07 | $374.00K derived: sum of 2 quarters · filed 2020-05-07 | $729.00K derived: sum of 3 quarters · filed 2020-05-07 | -$441.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $523.00K derived: sum of 2 quarters · filed 2020-03-12 | -$647.00K derived: sum of 3 quarters · filed 2020-03-12 | $1.28M 10-K · filed 2020-03-12 |
| 2018-09-30 | $355.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$815.00K derived: sum of 2 quarters · filed 2019-11-12 | $1.11M 10-Q · filed 2019-11-12 | -$119.00K derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | -$1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $753.00K 10-Q · filed 2019-08-14 | -$474.00K derived: sum of 3 quarters · filed 2019-08-14 | $774.00K derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $1.92M 10-Q · filed 2019-05-15 | $696.00K derived: sum of 2 quarters · filed 2019-05-15 | $1.94M derived: sum of 3 quarters · filed 2019-05-15 | |
| 2017-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | $21.00K derived: sum of 2 quarters · filed 2019-03-19 | $477.00K 10-K · filed 2019-03-19 | |
| 2017-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.70M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $456.00K 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |